Here's Why You Should Retain OPKO Health Stock in Your Portfolio Now
OPK leans on RAYALDEE momentum and strategic partnerships as pipeline trials advance, though reliance on its lone U.S. drug adds risk.
OPK Q3 Earnings Beat Estimates, Sales Miss, Gross Margin Expands
OPKO Health's Q3 earnings top estimates despite lower sales. Cost cuts and product strength boost margins and operating income.
OPKO Health, Inc. (OPK) Q3 2025 Earnings Call Transcript
OPKO Health, Inc. ( OPK ) Q3 2025 Earnings Call October 29, 2025 4:30 PM EDT Company Participants Phillip Frost - Chairman & CEO Elias Zerhouni - President & Vice Chairman Adam Logal - Senior VP & CFO Gary Nabel - Chief Information Officer & Director Conference Call Participants Yvonne Briggs - LHA Investor Relations Maurice Raycroft - Jefferies LLC, Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Kevin DeGeeter - Ladenburg Thalmann & Co. Inc., Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Yale Jen - Laidlaw & Company (UK) Ltd.
Compared to Estimates, OPKO Health (OPK) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) Q3 Earnings Surpass Estimates
OPKO Health (OPK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.03 per share a year ago.
Here's Why You Should Add OPKO Health Stock to Your Portfolio
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK benefits from RAYALDEE momentum, strategic deals and advancing trials amid stiff competition and dependence risks.
OPK Stock Slips Following Q2 Earnings Miss, Gross Margin Expands
OPKO Health reports wider-than-expected second-quarter 2025 loss and revenue decline, but gross margin expands and product sales remain stable.
OPKO Health, Inc. (OPK) Q2 2025 Earnings Call Transcript
OPKO Health, Inc. (NASDAQ:OPK ) Q2 2025 Earnings Conference Call July 31, 2025 4:30 PM ET Company Participants Adam E. Logal - Senior VP & CFO Elias Adam Zerhouni - President & Vice Chairman Phillip Frost - Chairman & CEO Yvonne Briggs - LHA Investor Relations Conference Call Participants Edward Andrew Tenthoff - Piper Sandler & Co., Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.
Compared to Estimates, OPKO Health (OPK) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) Reports Q2 Loss, Lags Revenue Estimates
OPKO Health (OPK) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.12. This compares to a loss of $0.01 per share a year ago.
Here's Why You Should Retain OPKO Health Stock in Your Portfolio
OPK's growth hinges on RAYALDEE and key partnerships, but rising competition and reliance on one drug pose risks.
